Clinical case report: Behсet’s Uveitis: Diagnostic Challenges and Modern Treatment Approach
https://doi.org/10.18008/1816-5095-2026-2-380-387
Abstract
The article analyzes the clinical observation of a 22-year-old patient with severe recurrent bilateral uveitis complicated by neuroretinitis, probably caused by Behcet’s disease. The presented data demonstrate significant diagnostic difficulties associated with the lack of pathognomonic laboratory markers of Behcet’s disease and the need for a comprehensive assessment of clinical and anamnestic data. The key role was played by the identification of the Human Leukocyte antigen (HLA) B51 allele, a genetic marker of predisposition to Behcet’s disease, in a patient from the Astrakhan region. Taking into account the resistance to glucocorticoids and the high risk of irreversible vision loss, a genetically engineered biological therapy with tumor necrosis factor (TNF)-alpha inhibitor adalimumab was initiated. As a result of the treatment, positive dynamics was achieved with complete restoration of visual acuity, regression of macular edema and signs of neuroretinitis according to optical coherence tomography. The observation highlights the importance of including Behcet’s disease in the differential diagnosis of recurrent uveitis in young patients, the importance of genetic testing for HLA-B51, and the expediency of early prescribing modern targeted drugs, primarily TNF-α inhibitors, to preserve visual functions. The key factor for successful treatment in this case was the coordinated interaction of ophthalmological and rheumatological specialists.
Keywords
About the Authors
D. S. Atarshchikov
MEDSI Group of Companies JSC
Russian Federation
Russian Federation
Atarshchikov Dmitry S. - PhD, ophthalmologist, ophthalmic surgeon, orbital surgeon, oculoplastic surgeon
Michurinsky Ave., 56/1, Moscow, 119192
E. S. Taskina
Chita State Medical Academy
Russian Federation
Russian Federation
Taskina Elizaveta S. - PhD, Associate Professor, Associate Professor of Ophthalmology Department, ophthalmologist
Gorky str., 39a, Chita, 672000
A. E. Egorov
Pirogov Russian Scientific Research Medical University
Russian Federation
Russian Federation
Egorov Alexey E. - MD, Professor, Professor of the Academician A.P. Nesterov Department of Ophthalmology, Institute of Clinical Medicine, ophthalmologist
Ostrovityanova str., 1, Moscow, 117513
N. A. Zubareva
Chita State Medical Academy
Russian Federation
Russian Federation
Zubareva Natalya A. - ophthalmologist
Gorky str., 39a, Chita, 672000
T. V. Beketova
Central Clinical Hospital with a Polyclinic, Presidential Property Management Department of the Russian Federation;
V.A. Nasonova Research Institute of Rheumatology;
Moscow Polytechnic University
Russian Federation
Russian Federation
Beketova Tatiana V. - MD, head of the Rheumatology Department with Nephrology Beds and a Room for Therapy with Genetically Engineered Biological Drugs, leading researcher, Professor of the Department of Infocognitive Technologies, rheumatologist
Marshala Timoshenko str., 19, bld. 1A, Moscow, 121359;
Kashirskoye Highway, 34A, Moscow, 115522;
Bolshaya Semyonovskaya str., 38, Moscow, 107023
References
1. Kiafar M, Faezi ST, Kasaeian A, Baghdadi A, Kakaei S, Mousavi SA, Nejadhosseinian M, Shahram F, Ghodsi SZ, Shams H, Davatchi F. Diagnosis of Behçet’s disease: clinical characteristics, diagnostic criteria, and differential diagnoses. BMC Rheumatol. 2021;5(1):2. doi: 10.1186/s41927-020-00172-1.
2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi: 10.1002/art.37715.
3. Razumova IYu, Godzenko AA. Behcet’s disease and uveitis. Russian Annals of Ophthalmology. 2021;137(5):130–137 (In Russ.). doi: 10.17116/oftalma2021137051130.
4. Chadli S, Maamar M, Abouqal R, Ammouri W, Tazi Mezalek Z, Harmouche H. Identification of clinical phenotypes in Behçet’s syndrome using latent class analysis: a step toward precision medicine. Clin Exp Rheumatol. 2025;43(10):1789–1798. doi: 10.55563/clinexprheumatol/3dhh59.
5. Hatemi G, Seyahi E, Fresko I, Talarico R, Uсar D, Hamuryudan V. Behcet’s syndrome: one year in review 2025. Clin Exp Rheumatol. 2025;43(10):1699–1708. doi: 10.55563/clinexprheumatol/8xuim0.
6. Nokhatha SAA, Aljaberi N, Zeyoudi JA, Almarzooqi A, Soukieh F, Khan M. High prevalence of HLA-B51 and ocular involvement in Behçet’s disease: a multicenter cross-sectional study. Rheumatol Int. 2025;45(6):140. doi: 10.1007/s00296-02505892-6.
7. Joubert M, Desbois AC, Domont F, Ghembaza A, Le Joncour A, Mirouse A, Maalouf G, Leclercq M, Touhami S, Cacoub P, Bodaghi B, Saadoun D. Behçet’s Disease Uveitis. J Clin Med. 2023;12(11):3648. doi: 10.3390/jcm12113648.
8. Lin S, Xu Z, Lin Z, Xie B, Feng J. Advances in pathogenesis and treatment of ocular involvement in Behcet’s disease. Front Immunol. 2023;14:1206959. doi: 10.3389/fimmu.2023.1206959.
9. Guan Y, Li F, Li N, Yang P. Decoding Behcet’s Uveitis: an In-depth review of pathogenesis and therapeutic advances. J Neuroinflammation. 2024;21(1):133. doi: 10.1186/s12974-024-03123-6.
10. Mahaju S, Achhami E, Lamichhane S, Chalise KN, Gautam R. A rare case of Behcet’s disease in Nepal: multisystem manifestations and diagnostic challenges. Ann Med Surg (Lond). 2023;85(10):5259–5262. doi: 10.1097/MS9.0000000000001279.
11. Çakar Ozdal P. Behçet’s Uveitis: Current Diagnostic and Therapeutic Approach. Turk J Ophthalmol. 2020;50(3):169–182. doi: 10.4274/tjo.galenos.2019.60308.
12. Zhong Z, Su G, Yang P. Risk factors, clinical features and treatment of Behçet’s disease uveitis. Prog Retin Eye Res. 2023;97:101216. doi: 10.1016/j.preteyeres.2023.101216.
13. Lisitsyna TA, Alekberova ZS, Davydova GA, Reshetnyak TM, Katargina LA, Nasonov EL. Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease. Nauchcno Practicheskaya Revmatologia. 2020;58(4):428–436 (In Russ.). doi: 10.47360/1995-4484-2020-428-436.
14. Scherrer MAR, Rocha VB, Garcia LC. Behçet’s disease: review with emphasis on dermatological aspects. An Bras Dermatol. 2017;92(4):452–464. doi: 10.1590/abd1806-4841.20177359.
15. D’Onghia M, Cinotti E, CartocciA, VitaleA, Caggiano V, Tognetti L, La Marca F, Sota J, Gentileschi S, Rubegni G, Lopalco G, Guerriero S, Govoni M, Monti S, Ruscitti P, Angeli F, Carubbi F, Giacomelli R, Ciccia F, Piga M, Emmi G, Costi S, Sebastiani GD, Iannone F, Spedicato V, Alessio G, Ruffilli F, MilanesiA, Gentile M, Crisafulli F, AlunnoA, Navarini L, Iacono D, Cauli A, Ricci F, Gaggiano C, Tarsia M, Bartoloni E, Conti G, Viapiana O, Gobbi FL, de Paulis A, Parronchi P, Del Giudice E, Barone P, Olivieri AN, Bizzi E, Maggio MC, Balistreri A, Frediani B, Tosi GM, Fabiani C, Rubegni P, Cantarini L. Unfolding dermatologic spectrum of Behçet’s disease in Italy: real-life data from the International AIDA Network Behçet’s disease Registry. Intern Emerg Med. 2023;18(8):2245–2252. doi: 10.1007/s11739-023-03410-9.
16. Siebert E, Moynihan V, Ali N, Hall A, Heydon P, Dunlop A, Lim LL, Richards J. Tattoo-Associated Uveitis: An Emerging Eye Health Challenge. Clin Exp Ophthalmol. 2026 Jan-Feb;54(1):33–43. doi: 10.1111/ceo.70012.
17. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018 Jun;77(6):808–818. doi: 10.1136/annrheumdis-2018-213225.
18. Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, Bienvenu B, Abad S, Rigolet A, Deroux A, Sene D, Perlat A, Marie I, Feurer E, Hachulla E, Fain O, Clavel G, Riviere S, Bouche PA, Gueudry J, Pugnet G, Le Hoang P, Resche Rigon M, Cacoub P, Bodaghi B, Saadoun D; French Uveitis Network. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. Arthritis Rheumatol. 2016;68(6):1522–1530. doi: 10.1002/art.39667.
19. Sulu B, Esatoglu S, Hatemi I, Celik A, Hatemi G. Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-of-jak-in‑hibitors-in-behcets-syndrome-a-systematic-literature-review/. Accessed January 18, 2026.
Review
For citations:
Atarshchikov D.S., Taskina E.S., Egorov A.E., Zubareva N.A., Beketova T.V. Clinical case report: Behсet’s Uveitis: Diagnostic Challenges and Modern Treatment Approach. Ophthalmology in Russia. 2026;23(2):380-387. (In Russ.) https://doi.org/10.18008/1816-5095-2026-2-380-387
Views:
10
JATS XML
Email this article 